| Developers: | Science Corp |
| Date of the premiere of the system: | October 2024 |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
Content |
2025: The Return of Vision to 27 Sufferers
At the end of October 2025, Science Corporation announced the development of a Prima implant that can return vision to visually impaired and blind people with retinal involvement. The product helped several dozen patients.
The Prima system targets people with so-called geographic atrophy: it is a progressive eye disease in which gradual degeneration of the central retina occurs, leading to vision loss. The ailment is a type of age-related macular degeneration (AMD), which is one of the most common causes of visual impairment in people over the age of 50. Due to pathological processes, changes occur in the retina that can lead to irreversible loss of central vision.
Prima technology provides for the use of a special implantable microchip 2 × 2 mm in size and augmented reality glasses with a built-in camera. The procedure involves a vitrectomy: this is surgery to remove the vitreous body of the eye (a clear gel that fills the eyeball) to access the retina. After implantation, the microchip receives images from the camera in glasses, converts light into electrical pulses and sends them to the brain.
After the procedure, each patient undergoes an intensive rehabilitation program for several months. One year after implantation, 81% of patients reportedly showed clinically significant improvement in visual acuity, and 84% demonstrated the ability to read letters, numbers or words. Overall, the system helped bring vision back to 27 people. It is emphasized that in the study participants there was no significant deterioration in the existing peripheral vision.[1]
2024: Product Announcement
On October 22, 2024, the American company Science Corp announced the development of a PRIMA retinal implant designed to treat age-related macular degeneration. The product helped to return the sight of dozens of people.
The PRIMA platform includes several key components. This is the implant itself - a wireless and fully autonomous photoelectric cell that is placed under the retina of the eye through a surgical procedure. Another component of the system is special glasses with a camera and a built-in projection module. The projector sends signals to the implanted device, allowing it to stimulate the retina. The third PRIMA component is a pocket computing unit for processing information.
The technology is based on the results of research by specialists from Stanford University. The implant is an array of 378 independently controlled pixels. They convert infrared light from the projector into electrical pulses. Thus, the glasses provide the implanted element with both visual data and energy necessary for operation.
The PRIMA system was used to restore visual acuity in 38 patients suffering from geographic atrophy. This is a late stage of age-related macular degeneration - a progressive and irreversible condition that affects the retina, leading to vision loss. Patients, in particular, lose the ability to distinguish between small details, which significantly impairs the quality of life. At the same time, the PRIMA implant returns the lost visual acuity, allowing patients, among other things, to read fluently.
 | The results demonstrate an important milestone in the treatment of severe vision loss caused by geographic atrophy due to age-related macular degeneration. For the first time, we managed to really restore vision, "said Professor Frank Holz, MD, scientific coordinator of the PRIMA study.[2] |  |
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |